AMGN · News · 20260804N
Guidance and Outlook
AMGEN INC · 2026-08-04 · Importance 69 · Surprise 60 · In source text
Amgen raised its full-year 2026 revenue outlook to $38.2 billion-$39.4 billion. Management also raised adjusted EPS guidance to $22.30-$23.50 after strong first-half product performance. The guidance increase followed second-quarter revenue of $10.05 billion, which exceeded the FactSet estimate of $9.43 billion. The company maintained its growth strategy despite approximately $7 billion of loss-of-exclusivity headwinds and biosimilar competition affecting older franchises.
Key facts
- Amgen raised its full-year 2026 revenue outlook to between $38.2 billion and $39.4 billion. source
- Reuters reported Q2 sales rose 9% year-over-year and Amgen raised its full-year revenue and profit outlook while discontinuing AMG 513. source
- Amgen said it is increasing spending on late-stage clinical programs and manufacturing capacity following Q2 2026 results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Amgen raised its full-year 2026 revenue outlook to between $38.2 billion and $39.4 billion. |